© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.
Take 5 minutes to catch up on NeurologyLive's highlights from the week ending February 26, 2021.
Welcome to NeurologyLive's Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive's widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.
"Mind Moments," a podcast from NeurologyLive, brings you an exclusive interview with Jennifer Martin, PhD, professor of medicine, University of California-Los Angeles, and a board member of the American Academy of Sleep Medicine (AASM), to discuss the AASM's recent clinical practice guideline update.
Investigators noted that empirical work is needed to determine if change from baseline, fixed time point assessments, and responder definitions, or other approaches optimize power and sensitivity to change.
The global head of medical affairs-neurology at Janssen Pharmaceutical discussed 2 studies presented at the ACTRIMS Forum 2021 involving fatigue among patients with multiple sclerosis.
The duo from Cleveland Clinic discussed their recently initiated study which will evaluate the neuroprotective features of home-based intervention in high-risk individuals for Alzheimer disease.
The effect of cladribine on CD8+ T lymphocytes varied by age, with steady increases shown in the younger population whereas there were fluctuations observed in the older group.
Evusheld Increased Attenuated SARS-CoV-2 Antibodies From MS B-Cell Depleting Medications
NeurologyLive® Friday 5 — June 24, 2022
Exploiting Anti-CD3 Antibodies, Relevant Biomarkers in Progressive MS: Tanuja Chitnis, MD
FDA Places Clinical Hold on Duchenne Muscular Dystrophy Drug SRP-5051 Amid Safety Concerns